CRBP

Corbus

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

consensus rating "Strong Buy"

RSI Overbought

EPS Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About CRBP

Corbus Pharmaceuticals Holdings, Inc.

An immunology company that develops novel therapeutics for the treatment of inflammatory diseases

Industry

Pharmaceutical

Established Date

04/24/2009

Listing Date

04/16/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.corbuspharma.com

Security Type

Common stock

Office address

500 River Ridge Drive , Norwood , Massachusetts 02062

Business

Introduction

Corbus Pharmaceuticals Holdings, Inc., was incorporated under the laws of the State of Delaware on April 24, 2009. Corbus is a precision oncology company with a diverse product portfolio dedicated to helping people beat serious diseases by bringing innovative scientific methods to widely understood biological pathways. The company's pipeline consists of two experimental drugs for solid tumors: CRB-701, a next-generation antibody-drug conjugate that targets the expression of Nectin-4 on cancer cells to release cytotoxic payloads, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells.

Company Financials

EPS

CRBP has released its 2024 Q4 earnings. EPS was reported at -0.78, versus the expected -1.26, beating expectations. The chart below visualizes how CRBP has performed over recent quarters, highlighting trends in earnings surprises.